Hecker, J.S., Hartmann, L., Riviere, J., Buck, M.C., van der Garde, M., Rothenberg-Thurley, M., Fischer, L., Winter, S., Ksienzyk, B., Ziemann, F., Solovey, M., Rauner, M., Tsourdi, E., Sockel, K., Schneider, M., Kubasch, A.S., Nolde, M., Hausmann, D., Paulus, A.C., Lutzner, J., Roth, A., Bassermann, F., Spiekermann, K., Marr, C., Hofbauer, L.C., Platzbecker, U., Metzeler, K.H., Gotze, K.S. (2021). Blood 138, 1727-1732.
Clonal hematopoiesis (CH) is an age-related condition predisposing to blood cancer and cardiovascular disease (CVD). Murine models demonstrate CH-mediated altered immune function and proinflammation. Low-grade inflammation has been implicated in the pathogenesis of osteoarthritis (OA), the main indication for total hip arthroplasty (THA). THA-derived hip bones serve as a major source of healthy hematopoietic cells in experimental hematology. We prospectively investigated frequency and clinical associations of CH in 200 patients without known hematologic disease who were undergoing THA. Prevalence of CH was 50%, including 77 patients with CH of indeterminate potential (CHIP, defined as somatic variant allele frequencies [VAFs] ≥2%), and 23 patients harboring CH with lower mutation burden (VAF, 1% to 2%). Most commonly mutated genes were DNMT3A (29.5%), TET2 (15.0%), and ASXL1 (3.5%). CHIP is significantly associated with lower hemoglobin, higher mean corpuscular volume, previous or present malignant disease, and CVD. Strikingly, we observed a previously unreported association of CHIP with autoimmune diseases (AIDs; multivariable adjusted odds ratio, 6.6; 95% confidence interval, 1.7-30; P = .0081). These findings underscore the association between CH and inflammatory diseases. Our results have considerable relevance for managing patients with OA and AIDs or mild anemia and question the use of hip bone–derived cells as healthy experimental controls.
